Project Grant R01CA305395
Award Date 8/7/26
Completion Date 7/31/30
Dollars Obligated $453K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
College Station, TX 77843, USA
Similar Awards
- The National Cancer Institute awarded Texas A&M Engineering Experiment Station $471,793 on July 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to investigate the role of nuclear architecture in regulating YAP/TAZ transcriptional programs in head and neck squamous cell carcinoma. The research addresses a gap in understanding how YAP1/TAZ activation triggers opposing cellular outcomes—tumor proliferation or epithelial-to-mesenchymal transition (EMT)—in...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $688,073 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop computational approaches that reconstruct the evolutionary history of cancer metastases. The project, led by Dr. Peter Van Loo, applies molecular archeology of cancer methods—DNA sequencing-based approaches that infer tumor evolutionary history—to metastatic disease. The work will advance understanding of how...
- The National Cancer Institute awarded the University of Texas Health Science Center at Houston $389,828 on September 15, 2025, under the Cancer Research Manpower program (CFDA 93.398) to model enhancer hijacking in cancer through genome engineering and single-cell sequencing. The award funds research led by Dr. Xu to investigate how structural variants rewire enhancer-promoter communication and drive oncogene activation in rearranged human genomes. The research employs CRISPR/CAS9 genome...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $621,121 on July 10, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate tumor-niche co-evolution mechanisms driving ovarian cancer metastasis and therapeutic resistance. The research integrates clonal barcoding, single-cell RNA sequencing, and in vivo CRISPR screens to trace the evolutionary trajectory of metastatic ovarian cancer cells and define niche adaptive changes that...
- The National Cancer Institute awarded William Marsh Rice University $385,102 on September 17, 2025, under the Cancer Research Manpower program (CFDA 93.398) to develop a single-cell assay for correlating genotype and phenotype of metastatic cancer cells in vivo using nanolaser optical barcodes. The project addresses technical bottlenecks in understanding metastatic cancer dynamics by developing laser particle technology to create unique optical barcodes enabling real-time tracking of migrating...
- The National Cancer Institute awarded William Marsh Rice University $149,190 on January 14, 2026, under the Cancer Research Manpower program (CFDA 93.398) to fund research investigating the relationship between advanced glycation end-products, extracellular matrix stiffness, and cancer progression in hyperglycemic conditions. The research, titled "Linking Mechanosensation and Cancer Progression in the Hyperglycemic Extracellular Matrix," examines how non-enzymatic addition of free...
- Grant Award Summary The National Cancer Institute (NCI) awarded $635,749 under the Cancer Biology Research program (CFDA 93.396) to The University of Texas Health Science Center at San Antonio for the project "Charting Cellular Attraction-Based Interactome with Multivalent Adhesive Probe AFM (MAPA)" (Award Date: September 1, 2025; Completion Date: August 31, 2028). This three-year Project Grant funds the development and validation of advanced atomic force microscopy (AFM) technology...
- The National Cancer Institute awarded the University of Texas at El Paso $573,746 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of N6-methyladenosine (M6A) modification in estrogen receptor activation and breast cancer progression. The research examines how M6A modification of enhancer RNAs facilitates phase-separated condensation of estrogen receptors, which is critical for assembling enhancer transcriptional machinery and regulating...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded $150,898 to the University of Texas at Austin on June 8, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify and validate gene activators of cancer cell-cell fusion that contribute to chromosomal instability and tumor evolution in triple negative breast cancer. The project will perform a pooled CRISPR activation screen in triple negative breast cancer cells to discover genes...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $226,884 on December 18, 2025, under the Cancer Research Manpower program (CFDA 93.398) to develop computational methods for reconstructing the evolutionary trajectory of focal amplifications and structural variants in cancer genomes. The project will produce two complementary approaches for evolutionary reconstruction: Amplicon Gain and Velocity Estimation (AGAVE), which will time when and how quickly...